| Literature DB >> 35122016 |
Priscilla K Brastianos1, Albert E Kim2, Daniel P Cahill2, Ryan J Sullivan2, Nancy Wang2, Eudocia Q Lee3, Jennifer Ligibel3, Justine V Cohen2,4, Ugonma N Chukwueke3, Maura Mahar2, Kevin Oh2, Michael D White2, Helen A Shih2, Deborah Forst2, Justin F Gainor2, Rebecca S Heist2, Elizabeth R Gerstner2, Tracy T Batchelor2, Donald Lawrence2, David P Ryan2, A John Iafrate2, Anita Giobbie-Hurder3, Sandro Santagata3, Scott L Carter3.
Abstract
Recent studies suggest that the cyclin-dependent kinase (CDK) pathway may be a therapeutic target for brain metastases (BM). Here, we present interim analysis of a basket trial evaluating the intracranial efficacy of the CDK inhibitor palbociclib in patients with progressive BM and CDK alterations. Our study met its primary endpoint and provides evidence for performing molecular testing of archival BM tissue, if available, to inform the choice of CNS-penetrant targeted therapy.Entities:
Mesh：
Substances：
Year: 2021 PMID： 35122016 DOI： 10.1038/s43018-021-00198-5
Source DB: PubMed Journal: Nat Cancer ISSN： 2662-1347